Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

The Natural History of Lower Risk MDS: Factors Predicting Progression to High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Very Low and Low Risk MDS According to the R-IPSS Criteria

Akriti G Jain, Somedeb Ball, Luis E. Aguirre, Najla Al Ali, David Kaldas, Sara Tinsley-Vance, Andrew T. Kuykendall, Onyee Chan, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami S. Komrokji

Blood (2021) 138 (Supplement 1): 2600.

https://doi.org/10.1182/blood-2021-149708

Published: 2021

Journal Articles

Supporting Adherence to Tyrosine Kinase Inhibitor (TKI) Therapy Among Patients with Chronic Myeloid Leukemia (CML)

Lisa Nodzon, PhD ARNP, AOCNP, Sara Tinsley-Vance, PhD ARNP, AOCN

Blood (2017) 130 (Supplement 1): 5624.

https://doi.org/10.1182/blood.V130.Suppl_1.5624.5624

Published: 2017

Journal Articles

A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes

Rami S Komrokji, MD, Sheng Wei, MD, Adam W Mailloux, PhD, Ling Zhang, MD, Eric Padron, MD, Jeffrey E. Lancet, MD, Sara Tinsley, ARNP, Lisa A Nardelli, BS, CCRP, Cynthia Benoit, RN, Javier Pinilla-Ibarz, MD PhD, Pearlie K Epling-Burnette, PhD, Alan F List, MD

Blood (2014) 124 (21): 4653.

https://doi.org/10.1182/blood.V124.21.4653.4653

Published: 2014

Journal Articles

Preliminary International Validation of the Quality of Life in Myelodysplasia Scale (QUALMS)

Gregory A. Abel, MD MPH, Fabio Efficace, PhD, Rena Buckstein, MD, Sara Tinsley, ARNP, Joseph G. Jurcic, MD, Yolanda Martins, PhD, David P. Steensma, MD, Corey D Watts, Azra Raza, MD, Alan F. List, MD, Robert J. Klaassen, MD FRCP

Blood (2014) 124 (21): 1328.

https://doi.org/10.1182/blood.V124.21.1328.1328

Published: 2014

Journal Articles

A Phase II Clinical Trial Of Lenalidomide and Prednisone In Low and Intermediate-1 IPSS Risk, Non-Del (5q) MDS Patients

Rami S Komrokji, MD, Najla H Al Ali, Eric Padron, MD, Ji-Hyun Lee, PhD, Nancy Hillgruber, RN, Sara Tinsley, ARNP, Jeffrey E Lancet, MD, Alan List, MD

Blood (2013) 122 (21): 1506.

https://doi.org/10.1182/blood.V122.21.1506.1506

Published: 2013

Journal Articles

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy

Kendra L. Sweet, MD, Najla H Al Ali, Jeffrey E Lancet, MD, Ben Creelan, MD, Sara Tinsley, ARNP, Bijal D. Shah, MD, Ling Zhang, MD, Rami S. Komrokji, MD, Javier Pinilla-Ibarz, MD, PhD

Blood (2012) 120 (21): 3740.

https://doi.org/10.1182/blood.V120.21.3740.3740

Published: 2012

Journal Articles

Adherence to Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia (CML)

Paul Jacobsen, Ph.D., Kendra L. Sweet, MD, Yun-Hsiang Lee, Ph.D., Sara Tinsley, ARNP, Jeffrey E Lancet, MD, Rami S. Komrokji, MD, Patricia Cabrera, Javier Pinilla-Ibarz, MD, PhD

Blood (2011) 118 (21): 4431.

https://doi.org/10.1182/blood.V118.21.4431.4431

Published: 2011

Journal Articles

Erlotinib for Treatment of Myelodysplastic Syndromes: A Phase II Clinical Study

Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, Daohai Yu, Ph.D, Enrique Santana, RN, Lulu Yan, MS, Pamela S Smith, RN, Sara Tinsley, ARNP, Darcie Deaver, ARNP, Ling Zhang, MD, Alan F. List, MD

Blood (2010) 116 (21): 1854.

https://doi.org/10.1182/blood.V116.21.1854.1854

Published: 2010

Journal Articles

Hematopathologic Evaluation of Myelodysplastic Features of Patients with CP-CML on Therapy with Clonal Cytogenetic Abnormalities In Ph Negative Clones

Monique A Hartley, MD, Ling Zhang, MD, William Bulkeley, III, MD, Bijal D. Shah, MD, Sara Tinsley, ARNP, Javier Pinilla-Ibarz, MD

Blood (2010) 116 (21): 1224.

https://doi.org/10.1182/blood.V116.21.1224.1224

Published: 2010

Journal Articles

Correlative Analysis of T Cell Subpopulations and CD20 Expression In a Phase II Study of Lenalidomide In Combination with Rituximab In Patients with Relapsed or Refractory CLL/SLL

Marays Veliz, M.D., John Powers, Ling Zhang, MD, Enrique Santana, RN, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Mohamed Kharfan-Dabaja, MD, Sara Tinsley, ARNP, Darcie Deaver, Eduardo M. Sotomayor, MD, Javier Pinilla-Ibarz, MD

Blood (2010) 116 (21): 4630.

https://doi.org/10.1182/blood.V116.21.4630.4630

Published: 2010

Journal Articles

Hypercalcemia Following Treatment with Lenalidomide in Chronic Lymphocytic Leukemia (CLL).

Bijal D. Shah, MD, Marays Veliz, MD, Ricardo Santana, Jeffrey E Lancet, MD, John J. Powers, B.S., Jason A Dubovsky, B.S., Sara Tinsley, Darcie Deaver, ANP, MS, Eduardo M. Sotomayor, MD, Javier Pinilla, MD, PhD

Blood (2009) 114 (22): 4413.

https://doi.org/10.1182/blood.V114.22.4413.4413

Published: 2009

Journal Articles

Phase II Study of Lenalidomide in Combination with Rituximab for Patients with CD5+/CD20+ Hematologic Malignancies Who Relapse or Progress After Rituximab. Interim Analysis.

Marays Veliz, MD, Ricardo Santana, Jeffrey E Lancet, MD, Rami S. Komrokji, MD, Mohamed A Kharfan-Dabaja, MD, John J. Powers, B.S., Jason A Dubovsky, B.S., Sara Tinsley, Darcie Deaver, ANP, MS, Eduardo M. Sotomayor, MD, Javier Pinilla-Ibarz, MD, PhD

Blood (2009) 114 (22): 2376.

https://doi.org/10.1182/blood.V114.22.2376.2376

Published: 2009

Journal Articles

A Retrospective Evaluation of Clonal Cytogenetic Abnormalities in Ph Negative Clones in Patients with CP-CML on Therapy

Monique A Hartley, MD, Bijal D. Shah, MD, Sady Armada, Sara Tinsley, Javier Pinilla, MD, PhD

Blood (2008) 112 (11): 4277.

https://doi.org/10.1182/blood.V112.11.4277.4277

Published: 2008

NARROW

The Natural History of Lower Risk MDS: Factors Predicting Progression to High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Very Low and Low Risk MDS According to the R-IPSS Criteria

Supporting Adherence to Tyrosine Kinase Inhibitor (TKI) Therapy Among Patients with Chronic Myeloid Leukemia (CML)

A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes

Preliminary International Validation of the Quality of Life in Myelodysplasia Scale (QUALMS)

A Phase II Clinical Trial Of Lenalidomide and Prednisone In Low and Intermediate-1 IPSS Risk, Non-Del (5q) MDS Patients

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy

Adherence to Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia (CML)

Erlotinib for Treatment of Myelodysplastic Syndromes: A Phase II Clinical Study

Hematopathologic Evaluation of Myelodysplastic Features of Patients with CP-CML on Therapy with Clonal Cytogenetic Abnormalities In Ph Negative Clones

Correlative Analysis of T Cell Subpopulations and CD20 Expression In a Phase II Study of Lenalidomide In Combination with Rituximab In Patients with Relapsed or Refractory CLL/SLL

Hypercalcemia Following Treatment with Lenalidomide in Chronic Lymphocytic Leukemia (CLL).

Phase II Study of Lenalidomide in Combination with Rituximab for Patients with CD5+/CD20+ Hematologic Malignancies Who Relapse or Progress After Rituximab. Interim Analysis.

A Retrospective Evaluation of Clonal Cytogenetic Abnormalities in Ph Negative Clones in Patients with CP-CML on Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only